Matthew K Siggins1, Simren K Gill1, Paul R Langford2, Yanwen Li2, Shamez N Ladhani3, John S Tregoning4. 1. Mucosal Infection & Immunity Group, Section of Virology, Imperial College London, St Mary's Campus, London W2 1PG, UK. 2. Section of Paediatrics, Imperial College London, London W2 1PG, UK. 3. Immunisation Department, Public Health England, Colindale, London NW9 5EQ, UK; Paediatric Infectious Diseases Research Group, St. George's University of London, SW17 0RE, UK. 4. Mucosal Infection & Immunity Group, Section of Virology, Imperial College London, St Mary's Campus, London W2 1PG, UK. Electronic address: john.tregoning@imperial.ac.uk.
Abstract
BACKGROUND: A recently-licensed 10-valent pneumococcal conjugate vaccine (PHiD-CV; Synflorix, GSK) uses Protein D from Haemophilus influenzae as a carrier protein. PHiD-CV therefore has the potential to provide additional protection against nontypeable H. influenzae (NTHi). NTHi frequently causes respiratory tract infections and is associated with significant morbidity and mortality worldwide and there is currently no vaccine. METHODS: We developed mouse models of NTHi infection and influenza/NTHi superinfection. Mice were immunized with PHiD-CV, heat-killed NTHi, or a 13-valent pneumococcal conjugate vaccine that did not contain Protein D (PCV13; Prevenar, Pfizer) and then infected intranasally with NTHi. RESULTS: Infection with NTHi resulted in weight loss, inflammation and airway neutrophilia. In a superinfection model, prior infection with pandemic H1N1 influenza virus (strain A/England/195/2009) augmented NTHi infection severity, even with a lower bacterial challenge dose. Immunization with PHiD-CV produced high levels of antibodies that were specific against Protein D, but not heat-killed NTHi. Immunization with PHiD-CV led to a slight reduction in bacterial load, but no change in disease outcome. CONCLUSIONS: PHiD-CV induced high levels of Protein D-specific antibodies, but did not augment pulmonary clearance of NTHi. We found no evidence to suggest that PHiD-CV will offer added benefit by preventing NTHi lung infection.
BACKGROUND: A recently-licensed 10-valent pneumococcal conjugate vaccine (PHiD-CV; Synflorix, GSK) uses Protein D from Haemophilus influenzae as a carrier protein. PHiD-CV therefore has the potential to provide additional protection against nontypeable H. influenzae (NTHi). NTHi frequently causes respiratory tract infections and is associated with significant morbidity and mortality worldwide and there is currently no vaccine. METHODS: We developed mouse models of NTHi infection and influenza/NTHi superinfection. Mice were immunized with PHiD-CV, heat-killed NTHi, or a 13-valent pneumococcal conjugate vaccine that did not contain Protein D (PCV13; Prevenar, Pfizer) and then infected intranasally with NTHi. RESULTS:Infection with NTHi resulted in weight loss, inflammation and airway neutrophilia. In a superinfection model, prior infection with pandemic H1N1 influenza virus (strain A/England/195/2009) augmented NTHi infection severity, even with a lower bacterial challenge dose. Immunization with PHiD-CV produced high levels of antibodies that were specific against Protein D, but not heat-killed NTHi. Immunization with PHiD-CV led to a slight reduction in bacterial load, but no change in disease outcome. CONCLUSIONS: PHiD-CV induced high levels of Protein D-specific antibodies, but did not augment pulmonary clearance of NTHi. We found no evidence to suggest that PHiD-CV will offer added benefit by preventing NTHi lung infection.
Authors: Simren K Gill; Kailyn Hui; Hugo Farne; James P Garnett; Deborah L Baines; Luke S P Moore; Alison H Holmes; Alain Filloux; John S Tregoning Journal: Sci Rep Date: 2016-06-08 Impact factor: 4.379
Authors: Laura Lambert; Ekaterina Kinnear; Jacqueline U McDonald; Gunnveig Grodeland; Bjarne Bogen; Elisabeth Stubsrud; Mona M Lindeberg; Agnete Brunsvik Fredriksen; John S Tregoning Journal: Front Immunol Date: 2016-08-23 Impact factor: 7.561
Authors: Candice Poux; Aleksandra Dondalska; Joseph Bergenstråhle; Sandra Pålsson; Vanessa Contreras; Claudia Arasa; Peter Järver; Jan Albert; David C Busse; Roger LeGrand; Joakim Lundeberg; John S Tregoning; Anna-Lena Spetz Journal: Front Immunol Date: 2019-09-12 Impact factor: 7.561
Authors: Helen T Groves; Jacqueline U McDonald; Pinky Langat; Ekaterina Kinnear; Paul Kellam; John McCauley; Joanna Ellis; Catherine Thompson; Ruth Elderfield; Lauren Parker; Wendy Barclay; John S Tregoning Journal: Front Immunol Date: 2018-01-31 Impact factor: 7.561
Authors: Karina Jawinski; Marcus Hartmann; Charanjit Singh; Ekaterina Kinnear; David C Busse; Annalisa Ciabattini; Fabio Fiorino; Donata Medaglini; Claudia Maria Trombetta; Emanuele Montomoli; Vanessa Contreras; Roger Le Grand; Celine Coiffier; Charlotte Primard; Bernard Verrier; John S Tregoning Journal: Front Immunol Date: 2019-11-13 Impact factor: 7.561